This clinical trial is focused on studying the treatment of HIV, which stands for Human Immunodeficiency Virus. The study is comparing two different medication regimens for adults who have not previously taken antiretroviral therapy, which is the treatment used to manage HIV. The first treatment being studied is a two-drug combination called Dovato, which contains the active substances lamivudine and dolutegravir sodium. The second treatment is a three-drug combination known as Biktarvy, which includes emtricitabine, tenofovir alafenamide, and bictegravir.
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of these two treatment regimens. Participants will be randomly assigned to receive either the two-drug or the three-drug regimen, and they will take their assigned medication once daily. The study will monitor the participants over a period of time to see how well the virus is controlled, as well as to observe any side effects or other health changes that may occur.
Throughout the study, the main goal is to determine if the two-drug regimen is not less effective than the three-drug regimen in controlling the virus in people who are new to antiretroviral therapy. Participants will have regular check-ups and tests to measure the amount of virus in their blood and to assess their overall health. The study aims to provide valuable information on the best treatment options for managing HIV in adults who are starting therapy for the first time.
Belgium 
Denmark 
France 
Germany 
Greece 
Ireland 
Italy 
Poland 
Portugal 
Spain 
Sweden